When was Beta Bionics founded?

Beta Bionics was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Beta Bionics located?

Beta Bionics is headquartered in Boston, United States. It is registered at Irvine, California.

How many employees does Beta Bionics have?

As of May 31, 2026, the latest employee count at Beta Bionics is 421.

Is Beta Bionics a funded company?

Beta Bionics is a funded company, having raised a total of $349M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 29, 2016.

When was the latest funding round of Beta Bionics?

Beta Bionics' latest funding was a $***** Series E round on Nov 13, 2024, with participation from 8 investors.

What is the annual revenue of Beta Bionics?

Annual revenue of Beta Bionics is between $10M and $50M as on Dec 31, 2023

Where does Beta Bionics rank among its competitors?

Beta Bionics ranks 1st amongst 6 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of Beta Bionics?

Beta Bionics' top competitors include Sernova, Betalin Therapeutics and Beta - O2. Among them, Sernova secured the most recent funding round in October, 2025.

Beta Bionics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Innovating diabetes management with automated bionic pancreas technology. The company pioneers the development of the iLet Bionic Pancreas, an insulin delivery system designed to simplify diabetes management. This innovative technology reduces the burden of decision-making for individuals with diabetes by automating insulin dosing based on continuous glucose monitoring data. The system learns individual insulin needs, eliminating the need for manual carb counting and corrections. The company is dedicated to improving the lives of people with diabetes through user-friendly technological solutions. They focus on creating a supportive community and providing resources for both patients and healthcare professionals. Their commitment extends to ongoing research, clinical trials, and continuous product development to enhance the effectiveness and accessibility of their bionic pancreas system. The company is focused on social impact by making diabetes management easier.

Website: www.betabionics.com/
Social
Registered Address: Irvine, California

Key Metrics

Founded Year

2015

Location

Boston, United States

Stage

Public

Total Funding

$349M in 10 rounds

Latest Funding Round

Series E, Nov 13, 2024, $*****

Investors

Eventide Asset Management & 19 more

Ranked

1^st among 6 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2023

Employee Count

421 as on May 31, 2026

Similar Companies

Sernova & 6 more

Exit Details

Public

View Beta Bionics' full profile

Beta Bionics is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Beta Bionics, Inc. CIN: 475386878 , United States, Active	Dec 26, 999	-	294 (As on Dec 31, 2024)	-
Beta Bionics, Inc. CIN: 223008392 , United States, Active	Feb 20, 2024	$100M - $500M (As on Dec 31, 2025)	-	-
Beta Bionics, Inc CIN: 0001674632 , United States, Active	Oct 21, 2015	$10M - $50M (As on Dec 31, 2023)	233 (As on Dec 31, 2023)	-
Beta Bionics, Inc. CIN: 6660941 , United States, Active	Dec 05, 2022	-	-	-

Beta Bionics got listed on Jan 30, 2025.

Click here to take a look at Beta Bionics's IPO in detail

Beta Bionics has raised a total funding of $349M over 10 rounds. Its first funding round was on Jul 29, 2016. Its latest funding round was a Series E round on Nov 13, 2024 for $*****. 8 investors participated in its latest round. Beta Bionics has 20 institutional investors.

Here is the list of recent funding rounds of Beta Bionics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2024	1713317	Series E	3345785	6790401	7193492	1427737
Aug 28, 2023	6621298	Series D	7516648	6794178	9835581	Soleus Capital & 6 more
Feb 16, 2022	1677106	Series C	1926992	7744781	Soleus Capital & 4 more	Pura Vida Investments & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Beta Bionics's funding rounds and investors

The founders of Beta Bionics are Toby Milgrome, Edward Raskin, Serafina Raskin and Ed Damiano.

Here are the details of Beta Bionics' key team members:

Toby Milgrome: Co-Founder of Beta Bionics.
Contact Info: 1 email address
Edward Raskin: Co-Founder, Board Member (2015-2020), Public Benefit Officer of Beta Bionics.
Serafina Raskin: Former Co-Founder of Beta Bionics.
Ed Damiano: Co-Founder & CEO of Beta Bionics.
Contact Info: 1 email address

View details of Beta Bionics's Founder profiles and Board Members

Beta Bionics' employee count trend

Beta Bionics has 421 employees as of May 26. Here is Beta Bionics's employee count trend over the years:

Uncover Beta Bionics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beta Bionics include Sernova, Betalin Therapeutics and Beta - O2. Here is the list of Top 10 competitors of Beta Bionics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beta Bionics 2015, Boston (United States), Public	Innovating diabetes management with automated bionic pancreas technology	$349M	Colt Ventures, Wellington & 18 others	71/100
2nd	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	62/100
3rd	Betalin Therapeutics 2015, Ramat Gan (Israel), Series A	Developer of a micro-pancreas for diabetes treatment	$6M	EIC Fund, Europa & 1 others	43/100
4th	Beta - O2 2004, Rosh Haayin (Israel), Series A	Developer of an artificial pancreas for releasing insulin	$2M	JDRF, Saints Capital & 4 others	39/100
5th	Inreda Diabetic 2003, Goor (Netherlands), Seed	Developer of a bi-hormonal artificial pancreas	-	UvA Ventures Holding, Wadinko & 1 others	34/100
6th	Defymed 2011, Strasbourg (France), Deadpooled	Developer of bio-artificial pancreas for diabetes type 1 treatment	$3.72M	JDRF, Capital Grand Est & 1 others	33/100
7th	XOStem 2018, Irvine (United States), Seed	Developer of stem cells and bio-artificial organs for treating diabetes	$1.3M	-	29/100
8th	Captix 2018, Sydney (Australia), Deadpooled	Developer of a bioartificial pancreas for the treatment of diabetes	-	-	17/100